In this article, we will discuss Rolapitant (Dosage Overview). So, let’s get started.
Rolapitant is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
The recommended dosage is 180 mg rolapitant administered approximately 1 to 2 hours prior to the start of chemotherapy.
• Administer in combination with dexamethasone and a 5-HT3 receptor
antagonist, see full prescribing information for dosing information.
• No dosage adjustment for dexamethasone is required.